721. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
作者: Heinz Zoller.;Myles Wolf.;Irina Blumenstein.;Christian Primas.;Stefan Lindgren.;Lars L Thomsen.;Walter Reinisch.;Tariq Iqbal.
来源: Gut. 2023年72卷4期644-653页
Intravenous iron-a common treatment for anaemia and iron deficiency due to inflammatory bowel disease (IBD)-can cause hypophosphataemia. This trial compared the incidence of hypophosphataemia after treatment with ferric carboxymaltose (FCM) or ferric derisomaltose (FDI).
722. Longitudinal transkingdom gut microbial approach towards decompensation in outpatients with cirrhosis.
作者: Jasmohan S Bajaj.;Marcela Peña-Rodriguez.;Alex La Reau.;Wendy Phillips.;Michael Fuchs.;Brian C Davis.;Richard K Sterling.;Masoumeh Sikaroodi.;Andrew Fagan.;Amirhossein Shamsaddini.;Zachariah Henseler.;Tonya Ward.;Puneet Puri.;Hannah Lee.;Patrick M Gillevet.
来源: Gut. 2023年72卷4期759-771页
First decompensation development is a critical milestone that needs to be predicted. Transkingdom gut microbial interactions, including archaeal methanogens, may be important targets and predictors but a longitudinal approach is needed.
725. Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding.
作者: Marika Rudler.;Virginia Hernández-Gea.;Bogdan Dumitru Procopet.;Alvaro Giráldez.;Lucio Amitrano.;Càndid Villanueva.;Luis Ibañez.;Gilberto Silva-Junior.;Joan Genesca.;Christophe Bureau.;Jonel Trebicka.;Rafael Bañares.;Aleksander Krag.;Elba Llop.;Wim Laleman.;Jose Maria Palazon.;Jose Castellote.;Susana Rodrigues.;Lise Lotte Gluud.;Carlos Noronha Ferreira.;Nouria Canete.;Manuel Rodríguez.;Arnulf Ferlitsch.;Jose Luis Mundi.;Henning Gronbaek.;Manuel Hernandez-Guerra.;Romano Sassatelli.;Alessandra Dell'era.;Marco Senzolo.;Juan G Abraldes.;Manuel Romero-Gómez.;Alexander Zipprich.;Meritxell Casas.;Helena Masnou.;Hélène Larrue.;Massimo Primignani.;Frederik Nevens.;Jose Luis Calleja.;Remy Schwarzer.;Christian Jansen.;Marie-Angèle Robic.;Irene Conejo.;Javier Martínez Gonzalez.;Maria Vega Catalina.;Agustín Albillos.;Edilmar Alvarado.;Maria Anna Guardascione.;Maxime Mallet.;Simona Tripon.;Georgina Casanovas.;Jaume Bosch.;Juan-Carlos Garcia-Pagan.;Dominique Thabut.; .
来源: Gut. 2023年72卷4期749-758页
A pre-emptive transjugular intrahepatic portosystemic shunt (pTIPS) reduces mortality in high-risk patients with cirrhosis (Child-Pugh C/B+active bleeding) with acute variceal bleeding (AVB). Real-life studies point out that <15% of patients eligible for pTIPS ultimately undergo transjugular intrahepatic portosystemic shunt (TIPS) due to concerns about hepatic encephalopathy (HE). The outcome of patients undergoing pTIPS with HE is unknown. We aimed to (1) assess the prevalence of HE in patients with AVB; (2) evaluate the outcome of patients presenting HE at admission after pTIPS; and (3) determine if HE at admission is a risk factor for death and post-TIPS HE.
727. Reply to Newman et al 'Response to epidemiology of inflammatory bowel disease in men with high-risk homosexual activity'.
作者: Emad Mansoor.;Scott A Martin.;Abe Perez.;Vu Quang Nguyen.;Jeffry A Katz.;Shubham Gupta.;Fabio Cominelli.
来源: Gut. 2023年72卷11期2187-2188页 730. Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance.
作者: Chao-Yang Meng.;Shiyu Sun.;Yong Liang.;Hairong Xu.;Chao Zhang.;Min Zhang.;Fu-Sheng Wang.;Yang-Xin Fu.;Hua Peng.
来源: Gut. 2023年72卷8期1544-1554页
The purpose of this study is to develop an anti-PDL1-based interferon (IFN) fusion protein to overcome the chronic hepatitis B virus (HBV)-induced immune tolerance, and combine this immunotherapy with a HBV vaccine to achieve the functional cure of chronic hepatitis B (CHB) infection.
732. APC mosaicism, not always isolated: two first-degree relatives with apparently distinct APC mosaicism.
作者: Diantha Terlouw.;Frederik J Hes.;Manon Suerink.;Arnoud Boot.;Alexandra M J Langers.;Carli M Tops.;Monique E van Leerdam.;Christi J van Asperen.;Steve G Rozen.;Emilia K Bijlsma.;Tom van Wezel.;Hans Morreau.;Maartje Nielsen.
来源: Gut. 2023年72卷11期2186-2187页 733. Irritable bowel syndrome: treatment based on pathophysiology and biomarkers.
To appraise the evidence that pathophysiological mechanisms and individualised treatment directed at those mechanisms provide an alternative approach to the treatment of patients with irritable bowel syndrome (IBS).
735. Rates of repeated colonoscopies to clean the colon from low-risk and high-risk adenomas: results from the EPoS trials.
作者: Frederik Emil Juul.;Kjetil Garborg.;Eugen Nesbakken.;Magnus Løberg.;Paulina Wieszczy.;Joaquín Cubiella.;Mette Kalager.;Michael F Kaminski.;Rune Erichsen.;Hans-Olov Adami.;Monika Ferlitsch.;Siv K B Furholm.;Ann G Zauber.;Enrique Quintero.;Marek Bugajski.;Øyvind Holme.;Evelien Dekker.;Rodrigo Jover.;Michael Bretthauer.
来源: Gut. 2023年72卷5期951-957页
High-quality colonoscopy (adequate bowel preparation, whole-colon visualisation and removal of all neoplastic polyps) is a prerequisite to start polyp surveillance, and is ideally achieved in one colonoscopy. In a large multinational polyp surveillance trial, we aimed to investigate clinical practice variation in number of colonoscopies needed to enrol patients with low-risk and high-risk adenomas in polyp surveillance.
736. Use of over-the-scope clip (OTSC) versus standard therapy for the prevention of rebleeding in large peptic ulcers (size ≥1.5 cm): an open-labelled, multicentre international randomised controlled trial.
作者: Shannon Chan.;Rapat Pittayanon.;Hsiu-Po Wang.;Jiann-Hwa Chen.;Anthony Yb Teoh.;Yu Ting Kuo.;Raymond Sy Tang.;Hon Chi Yip.;Stephen Ka Kei Ng.;Sunny Wong.;Joyce Wing Yan Mak.;Heyson Chan.;Louis Lau.;Rashid N Lui.;Marc Wong.;Rungsun Rerknimitr.;Enders K Ng.;Philip Wai Yan Chiu.
来源: Gut. 2023年72卷4期638-643页
Over-the-scope clip (OTSC) has been used recently for primary haemostasis of peptic ulcers. This study aimed to compare the efficacy of OTSC to standard endoscopic therapy in primary treatment of patients with peptic ulcer bleeding that are of size ≥1.5 cm. The target population accounts for only 2.5% of all upper GI bleeders.
737. Targeting tumour-intrinsic N7-methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy.
作者: Haining Liu.;Xuezhen Zeng.;Xuxin Ren.;Yifan Zhang.;Manling Huang.;Li Tan.;Zihao Dai.;Jiaming Lai.;Wenxuan Xie.;Zebin Chen.;Sui Peng.;Lixia Xu.;Shuling Chen.;Shunli Shen.;Ming Kuang.;Shuibin Lin.
来源: Gut. 2023年72卷8期1555-1567页
Intrahepatic cholangiocarcinoma (ICC) exhibits very low response rate to immune checkpoint inhibitors (ICIs) and the underlying mechanism is largely unknown. We investigate the tumour immune microenvironment (TIME) of ICCs and the underlying regulatory mechanisms with the aim of developing new target to inhibit tumour growth and improve anti-programmed cell death protein-1 (PD-1) efficacy.
738. Most excess years of potential life loss among individuals with cirrhosis during the pandemic were not related to COVID-19.
作者: Yunyu Zhao.;Yee Hui Yeo.;Jamil Samaan.;Fan Lv.;Xinyuan He.;Ning Gao.;Justin Park.;Ju Dong Yang.;Walid Ayoub.;Michelle C Odden.;Fanpu Ji.;Mindie H Nguyen.
来源: Gut. 2023年72卷8期1628-1630页 739. Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases.
作者: Chloé Michaudel.;Camille Danne.;Allison Agus.;Aurélie Magniez.;Anne Aucouturier.;Madeleine Spatz.;Antoine Lefevre.;Julien Kirchgesner.;Nathalie Rolhion.;Yazhou Wang.;Aonghus Lavelle.;Chloé Galbert.;Gregory Da Costa.;Maxime Poirier.;Alexia Lapière.;Julien Planchais.;Petr Nádvorník.;Peter Illes.;Cyriane Oeuvray.;Laura Creusot.;Marie-Laure Michel.;Nicolas Benech.;Anne Bourrier.;Isabelle Nion-Larmurier.;Cecilia Landman.;Mathias L Richard.;Patrick Emond.;Philippe Seksik.;Laurent Beaugerie.;Rafael Rose Arguello.;David Moulin.;Sridhar Mani.;Zdenek Dvorák.;Luis G Bermúdez-Humarán.;Philippe Langella.;Harry Sokol.
来源: Gut. 2023年72卷7期1296-1307页
The extent to which tryptophan (Trp) metabolism alterations explain or influence the outcome of inflammatory bowel diseases (IBDs) is still unclear. However, several Trp metabolism end-products are essential to intestinal homeostasis. Here, we investigated the role of metabolites from the kynurenine pathway.
740. Epithelial presenilin-1 drives colorectal tumour growth by controlling EGFR-COX2 signalling.
作者: Reyes Gamez-Belmonte.;Mousumi Mahapatro.;Lena Erkert.;Miguel Gonzalez-Acera.;Elisabeth Naschberger.;Yuqiang Yu.;Mireia Tena-Garitaonaindia.;Jay V Patankar.;Yara Wagner.;Eva Podstawa.;Lena Schödel.;Marvin Bubeck.;Markus F Neurath.;Michael Stürzl.;Christoph Becker.
来源: Gut. 2023年72卷6期1155-1166页
Psen1 was previously characterised as a crucial factor in the pathogenesis of neurodegeneration in patients with Alzheimer's disease. Little, if any, is known about its function in the gut. Here, we uncovered an unexpected functional role of Psen1 in gut epithelial cells during intestinal tumourigenesis.
|